We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Moderna's First Cancer Therapy Win FDA Approval in 2027?
Read MoreHide Full Article
Key Takeaways
Moderna and Merck aim to file an FDA application for intismeran by year-end 2026.
Phase III results showed intismeran plus Keytruda cut recurrence or death risk by 42%.
Manufacturing capacity, patient turnaround times and commercialization plans remain key challenges.
Moderna (MRNA - Free Report) provided investors with an encouraging update during its third-quarter 2026 earnings call. Management said it is working with its partner Merck (MRK - Free Report) to submit a regulatory filing with the FDA for its personalized cancer therapy, intismeran autogene, by year-end 2026. If filed on time, intismeran could move toward potential approval in 2027.
However, the bigger question is whether this timeline is achievable. While the timing will depend primarily on the FDA's review, it will also depend on Moderna and Merck's ability to manufacture and deliver an individualized treatment within a commercially viable timeframe.
What Does Moderna Need to Do to Secure FDA Approval?
To seek approval, the companies must submit a biologics license application (BLA) containing evidence supporting the therapy's safety and effectiveness, along with information on manufacturing, quality controls and proposed labeling. The BLA must also include relevant nonclinical and clinical data to support the proposed use.
The FDA generally conducts an initial 60-day filing review to determine whether an application is sufficiently complete for substantive review. Once accepted, standard applications have a 10-month review goal compared with six months for priority review.
Based on the FDA's review timelines, a late-2027 decision could be possible if the partners submit the BLA sufficiently early and the application is accepted promptly for standard review. However, the FDA's initial filing review can take up to 60 days, after which the 10-month standard-review clock begins. Consequently, a submission toward the end of December 2026 could potentially push the regulatory decision into early 2028. The timeline will also depend on whether the FDA identifies issues that require additional information or a longer review.
The BLA will be supported by positive results from the phase III INTerpath-001 study, which evaluated intismeran plus Merck’s Keytruda in patients with high-risk (Stage IIB-IV) melanoma whose tumors had been surgically removed. The combination reduced the risk of recurrence or death by 42% and the risk of distant metastasis or death by 38% compared with Keytruda alone.
Management said the partners are preparing the submission and getting ready for pre-approval inspections. Both companies also have resources to support the program, while Merck brings substantial oncology development and commercialization experience through its established cancer franchise.
Can Moderna and Merck Manufacture and Deliver a Personalized Therapy at Scale?
Unlike conventional medicines produced in large batches, intismeran is tailored to each patient's tumor. The process involves analyzing tumor information, selecting relevant neoantigens, designing an individualized mRNA treatment and manufacturing it for that patient. The time required for these steps could influence how quickly patients receive treatment.
Moderna is also strengthening its manufacturing leadership ahead of the potential commercialization of intismeran. Juan Andres recently returned to the company as chief operating officer and will lead its manufacturing organization. During his previous tenure, Andres helped scale Moderna's manufacturing network and develop individualized manufacturing capabilities for intismeran. His return could support the company's efforts to prepare for commercial production. Moderna also plans to showcase its Marlborough manufacturing site at its Nov. 12 analyst event, potentially providing investors with greater insight into its manufacturing readiness. However, important details, including commercial production capacity, manufacturing costs and patient turnaround times, remain undisclosed.
Commercialization remains another uncertainty. The partners will need an efficient process for collecting patient samples, manufacturing individualized doses and delivering them to treatment centers. Pricing has also not been determined. During its third-quarter earnings conference call, Moderna’s management said it was too early to provide guidance and that the partners would assess the therapy's value to healthcare systems. These factors could influence patient access, adoption and intismeran's eventual revenue contribution.
Oncology Could Diversify Moderna’s Seasonal Vaccine Business
A successful oncology franchise could provide Moderna with another source of revenues with a different demand profile. If approved, intismeran could help diversify the company’s revenue base and reduce its reliance on seasonal respiratory vaccines. Although the company's respiratory vaccine portfolio currently spans COVID-19, RSV and influenza, it faces stiff competition from larger and more established players like Pfizer (PFE - Free Report) , Sanofi (SNY - Free Report) and GSK.
MRNA’s Price Performance, Valuation & Estimates
Shares of Moderna have skyrocketed more than 760% year-to-date, significantly outperforming the industry’s nearly 9% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, the company is currently trading at a premium to the industry. Based on the price-to-sales (P/S) ratio, the stock trades at 38.88 times forward 12-month sales, higher than the industry average of 2.00 times.
Image Source: Zacks Investment Research
Estimates for Moderna’s 2026 loss have remained consistent at $8.31 per share in the past 30 days. During the same time frame, those for 2027 have improved from $4.48 to $4.42.
View the Zacks #1 Rank List
Image: Bigstock
Can Moderna's First Cancer Therapy Win FDA Approval in 2027?
Key Takeaways
Moderna (MRNA - Free Report) provided investors with an encouraging update during its third-quarter 2026 earnings call. Management said it is working with its partner Merck (MRK - Free Report) to submit a regulatory filing with the FDA for its personalized cancer therapy, intismeran autogene, by year-end 2026. If filed on time, intismeran could move toward potential approval in 2027.
However, the bigger question is whether this timeline is achievable. While the timing will depend primarily on the FDA's review, it will also depend on Moderna and Merck's ability to manufacture and deliver an individualized treatment within a commercially viable timeframe.
What Does Moderna Need to Do to Secure FDA Approval?
To seek approval, the companies must submit a biologics license application (BLA) containing evidence supporting the therapy's safety and effectiveness, along with information on manufacturing, quality controls and proposed labeling. The BLA must also include relevant nonclinical and clinical data to support the proposed use.
The FDA generally conducts an initial 60-day filing review to determine whether an application is sufficiently complete for substantive review. Once accepted, standard applications have a 10-month review goal compared with six months for priority review.
Based on the FDA's review timelines, a late-2027 decision could be possible if the partners submit the BLA sufficiently early and the application is accepted promptly for standard review. However, the FDA's initial filing review can take up to 60 days, after which the 10-month standard-review clock begins. Consequently, a submission toward the end of December 2026 could potentially push the regulatory decision into early 2028. The timeline will also depend on whether the FDA identifies issues that require additional information or a longer review.
The BLA will be supported by positive results from the phase III INTerpath-001 study, which evaluated intismeran plus Merck’s Keytruda in patients with high-risk (Stage IIB-IV) melanoma whose tumors had been surgically removed. The combination reduced the risk of recurrence or death by 42% and the risk of distant metastasis or death by 38% compared with Keytruda alone.
Management said the partners are preparing the submission and getting ready for pre-approval inspections. Both companies also have resources to support the program, while Merck brings substantial oncology development and commercialization experience through its established cancer franchise.
Can Moderna and Merck Manufacture and Deliver a Personalized Therapy at Scale?
Unlike conventional medicines produced in large batches, intismeran is tailored to each patient's tumor. The process involves analyzing tumor information, selecting relevant neoantigens, designing an individualized mRNA treatment and manufacturing it for that patient. The time required for these steps could influence how quickly patients receive treatment.
Moderna is also strengthening its manufacturing leadership ahead of the potential commercialization of intismeran. Juan Andres recently returned to the company as chief operating officer and will lead its manufacturing organization. During his previous tenure, Andres helped scale Moderna's manufacturing network and develop individualized manufacturing capabilities for intismeran. His return could support the company's efforts to prepare for commercial production. Moderna also plans to showcase its Marlborough manufacturing site at its Nov. 12 analyst event, potentially providing investors with greater insight into its manufacturing readiness. However, important details, including commercial production capacity, manufacturing costs and patient turnaround times, remain undisclosed.
Commercialization remains another uncertainty. The partners will need an efficient process for collecting patient samples, manufacturing individualized doses and delivering them to treatment centers. Pricing has also not been determined. During its third-quarter earnings conference call, Moderna’s management said it was too early to provide guidance and that the partners would assess the therapy's value to healthcare systems. These factors could influence patient access, adoption and intismeran's eventual revenue contribution.
Oncology Could Diversify Moderna’s Seasonal Vaccine Business
A successful oncology franchise could provide Moderna with another source of revenues with a different demand profile. If approved, intismeran could help diversify the company’s revenue base and reduce its reliance on seasonal respiratory vaccines. Although the company's respiratory vaccine portfolio currently spans COVID-19, RSV and influenza, it faces stiff competition from larger and more established players like Pfizer (PFE - Free Report) , Sanofi (SNY - Free Report) and GSK.
MRNA’s Price Performance, Valuation & Estimates
Shares of Moderna have skyrocketed more than 760% year-to-date, significantly outperforming the industry’s nearly 9% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, the company is currently trading at a premium to the industry. Based on the price-to-sales (P/S) ratio, the stock trades at 38.88 times forward 12-month sales, higher than the industry average of 2.00 times.
Image Source: Zacks Investment Research
Estimates for Moderna’s 2026 loss have remained consistent at $8.31 per share in the past 30 days. During the same time frame, those for 2027 have improved from $4.48 to $4.42.
Image Source: Zacks Investment Research
Moderna currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.